Piramal starts phase-II trials for type-2 diabetes drug
22 Sep 2010
Piramal Life Sciences today said it has started phase-II clinical trials of a molecule, for treatment in diabetes, in Europe and India.
The company has initiated the phase-II study of 'P1736-05', an insulin sensitising compound, being developed for the treatment of type-2 diabetes, in India and Europe, Piramal reported in a filing to the Bombay Stock Exchange (BSE) today.
Piramal Life Sciences managing director, Somesh Sharma said the commencement of phase-II trials of P1736-05 in India and Europe spoke of the company's efforts in building a diversified and strong pipeline of products to address unmet medical needs.
He further added that the molecule was likely to provide an effective therapeutic option to type-2 diabetes patients.
The World Health Organisation (WHO) says, Type-2 diabetes, diabetes mellitus is a health crisis of global proportions with a projected incidence rate of 300 million by 2025.
Type-2 or non-insulin dependent diabetes patients constitute around 95 per cent of the global diabetic population.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
